Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 166 to 180 of 284 results for coronavirus

  1. Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer (TA801)

    Evidence-based recommendations on pembrolizumab (Keytruda) with paclitaxel or nab-paclitaxel for triple-negative, locally recurrent unresectable or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.

  2. Guidance executive

    NICE's guidance executive is made up of executive directors, guidance centre directors and senior team members.

  3. Perioperative care in adults (QS216)

    This quality standard covers care in adults during the preoperative, intraoperative and postoperative periods. It describes high-quality care in priority areas for improvement.

  4. Advocacy services for adults with health and social care needs (NG227)

    This guideline covers advocacy for people using health and social care services in all adult settings (including young people under 18 using adult services). It describes how to commission and deliver effective advocacy, as well as identifying who should be offered advocacy (including who is legally entitled to it). It also covers monitoring and improving advocacy services, and training and skills for advocates and practitioners.

  5. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management (NG206)

    This guideline covers diagnosing and managing myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS) in children, young people and adults. It aims to improve awareness and understanding about ME/CFS and when to suspect it, so that people are diagnosed earlier. It includes recommendations on diagnosis, assessment and care planning, safeguarding, access to care and managing ME/CFS and its symptoms.

  6. Patient Status Engine for wireless monitoring of vital signs (MIB271)

    NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .

  7. Lifelight First for monitoring vital signs (MIB213)

    NICE has developed a medtech innovation briefing (MIB) on Lifelight First for monitoring vital signs .

  8. Executive team

    Day-to-day decision making is the responsibility of NICE's executive team.

  9. Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)

    Evidence-based recommendations on fostamatinib (Tavlesse) for chronic refractory chronic immune thrombocytopenia in adults.

  10. Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and over (TA1054)

    Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.

  11. AposHealth for knee osteoarthritis (HTG671)

    Evidence-based recommendations on AposHealth for knee osteoarthritis.

  12. Postnatal care (NG194)

    This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.

  13. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

  14. What are the harms and adverse effects associated with different digital and mobile health behaviour change interventions?

    This question is more significant in light of the current context of the COVID-19 pandemic because the committee expect...

  15. Non-Hodgkin lymphoma: diagnosis and management (NG52)

    This guideline covers diagnosing, staging and managing non-Hodgkin lymphoma (NHL) in people aged 16 years and over. It includes radiotherapy, systemic anticancer therapy and stem cell transplantation treatments for follicular, MALT, mantle cell, diffuse large B-cell, Burkitt and peripheral T-cell lymphoma.